Page last updated: 2024-08-23

selegiline and Acute Confusional Senile Dementia

selegiline has been researched along with Acute Confusional Senile Dementia in 125 studies

Research

Studies (125)

Timeframe	Studies, this research(%)	All Research%
pre-1990	8 (6.40)	18.7374
1990's	57 (45.60)	18.2507
2000's	34 (27.20)	29.6817
2010's	23 (18.40)	24.3611
2020's	3 (2.40)	2.80

Authors

Authors	Studies
Chorev, M; Finberg, J; Finkelstein, N; Friedman, R; Goldenberg, W; Goren, T; Gross, A; Herzig, Y; Huang, W; Krais, B; Lavian, G; Lerner, D; Miskolczi, I; Molnar, S; Rantal, F; Razin, M; Sterling, J; Tamas, T; Toth, G; Weinstock, M; Youdim, MB; Zagyva, A; Zekany, A	1
Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V	1
Huang, L; Jiang, H; Li, X; Lu, C; Luo, Z; Mao, F; Shan, W; Su, T; Sun, Y	1
Bautista-Aguilera, OM; Esteban, G; Fernández Fernández, AP; Herrero, R; Inokuchi, T; Iriepa, I; Marco-Contelles, J; Moraleda, I; Ojima, M; Romero, A; Samadi, A; Soriano, E; Unzeta, M; Wang, L; Youdim, MB	1
Chen, J; Huang, L; Li, X; Su, T; Wang, Y; Wang, Z; Xie, S	1
Estrada, M; Herrera-Arozamena, C; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI; Romero, A; Viña, D	1
Foka, GB; Joubert, J; Kapp, E; Malan, SF; Oliver, DW; Repsold, BP	1
de Andrés, L; Estrada Valencia, M; Herrera-Arozamena, C; Laurini, E; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Pricl, S; Ramos, E; Rodríguez-Franco, MI; Romero, A; Viña, D; Yáñez, M	1
Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME	1
Almkvist, O; Ferreira, D; Fortea, J; Graff, C; Lleó, A; Montal, V; Nordberg, A; Rodriguez-Vieitez, E; Vilaplana, E; Wall, A; Westman, E	1
Han, W; Li, H; Yang, H	1
Dyrks, T; Marutle, A; Ni, R; Nordberg, A; Röjdner, J; Thiele, A; Voytenko, L	1
Comley, RA; Gauthier, S; Guiot, MC; Guo, Q; Harada, R; Kang, MS; Massarweh, G; Mathotaarachchi, S; Ng, KP; Okamura, N; Pascoal, TA; Rosa-Neto, P; Shin, M; Soucy, JP; Therriault, J	1
Aversa, D; Berretta, N; Cavallucci, V; Coccurello, R; Cordella, A; Cutuli, D; D'Amelio, M; De Bartolo, P; Dell'Acqua, MC; Federici, M; Giacovazzo, G; Keller, F; Krashia, P; Latagliata, EC; Marino, R; Mercuri, NB; Nobili, A; Petrosini, L; Puglisi-Allegra, S; Rizzo, FR; Sancandi, M; Viscomi, MT	1
Gillberg, PG; Lemoine, L; Nennesmo, I; Nordberg, A; Saint-Aubert, L	1
Cho, J; Cho, S; Cho, SJ; Choi, JW; Chun, H; Hwang, SY; Jang, BK; Jo, S; Ju, YH; Kim, HJ; Kim, J; Kim, S; Kim, SW; Lee, C; Lee, CJ; Londhe, AM; Nam, MH; Oh, SJ; Pae, AN; Park, JH; Park, KD; Park, M; Shin, SJ; Song, HJ; Woo, J; Yarishkin, O; Yeon, SK	1
Du, Z; Huang, L; Li, X; Lu, C; Yan, J; Zhou, Q	1
Bergfors, A; Gillberg, PG; Marutle, A; Nennesmo, I; Ni, R; Nordberg, A; Voytenko, L; Yu, W	1
da Cunha, C; Ferreira, AP; Ferreira, J; Gomes, GM; Mello, CF; Pazini, AM; Pinheiro, F; Rubin, MA; Villarinho, JG	1
Carter, SF; Choo, IL; Nordberg, A; Schöll, ML	1
Almkvist, O; Carter, SF; Chiotis, K; Långström, B; Leuzy, A; Nordberg, A; Rodriguez-Vieitez, E; Saint-Aubert, L; Schöll, M; Wall, A	1
Miklya, I	2
Feldman, HH; Hsiung, GY	1
Haltia, T; Hirvonen, J; Kailajärvi, M; Koskimies, S; Någren, K; Oikonen, V; Rinne, JO; Ruokoniemi, P; Scheinin, M; Sipilä, H; Virsu, P; Virtanen, K	1
Ba, MW; Sun, ZK; Xing, Y; Xu, J; Yang, HQ	1
Bakota, L; Gulya, K; Gulyás, B; Halldin, C; Hermecz, I; Horváth, MC; Kása, P; Keller, E; Magyar, K; Nag, S; Pavlova, E; Várszegi, S	1
Andrieux, K; Brambilla, D; Couvreur, P; Le Droumaguet, B; Nicolas, J; Souguir, H; Taverna, M; Verpillot, R	1
Engler, H; Gambini, JP; Kilander, L; Långström, B; Lannfelt, L; Santillo, AF; Ulla-Marja, L	1
Almkvist, O; Carter, SF; Engler, H; Långström, B; Nordberg, A; Schöll, M; Wall, A	1
Borges, F; Cadoni, E; Ferino, G; Laguna, R; Matos, MJ; Santana, L; Uriarte, E; Viña, D	1
Efimenko, VN; Evtushenko, SK; Kazarian, NE; Lutskiĭ, IS	1
Birks, J; Flicker, L	2
Iida, Y; Saji, H	1
Boda, K; Janka, Z; Juhász, A; Kálmán, J; Márki-Zay, J; Palotás, A; Palotás, M; Rimanóczy, A; Szabó, Z	1
Sano, M	1
DeLaGarza, VW	1
Hatakeyama, Y; Nakano, N; Yoshida, T	1
Kitamura, S	1
Shen, ZX	1
Arya, P; Butler, R; Warner, J	1
Gaszner, P; Miklya, I	1
Casarett, DJ; Hirschman, KB; James, BD; Joyce, CM; Karlawish, JH; Xie, SX	1
Barcikowska, M; Gabryelewicz, T; Jarczewska, DL	1
Butler, R; Warner, J; Wuntakal, B	1
Tariot, PN	1
Youdim, MB	1
Ames, D; Ritchie, C	1
Ashani, Y; Groner, E; Herzig, Y; Schorer-Apelbaum, D; Sterling, J; Weinstock, M	1
Dell'Antone, P; Drago, D; IbnLkayat, M; Zatta, P	1
Mouri, A; Nabeshima, T; Noda, Y; Tsunekawa, H; Yoneda, F	1
Jellinger, K; Riederer, P	1
Obenberger, J; Roth, J	1
Knoll, J	6
Berry, MD; Juorio, AV; Paterson, IA	1
Chiueh, CC; Mohanakumar, KP; Murphy, DL; Wu, RM	1
Goldstein, B; Schneider, LS; Tariot, PN	1
Bayer, BL; Burke, WJ; Ranno, AE; Roccaforte, WH; Wengel, SP; Willcockson, NK	2
Hajba, A; Heinonen, EH; Kotila, M; Savijärvi, M; Scheinin, M	1
Olin, JT; Pawluczyk, S; Schneider, LS	1
Lieberman, A	1
Cummings, JL	2
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Bierer, LM; Davis, KL; Jacobson, R; Lawlor, BA; Marin, DB; Mohs, RC; Ryan, TM; Schmeidler, J	1
Bruyette, DS; Cotman, CW; Cummings, BJ; DePaoli, A; Head, E; Milgram, NW; Ruehl, WW	1
Ernesto, C; Growdon, J; Grundman, M; Klauber, MR; Sano, M; Schafer, K; Thal, LJ; Thomas, R; Woodbury, P	1
Chalmers-Redman, RM; Ju, WY; Tatton, NA; Tatton, WG; Wadia, JS	1
Kuhn, W; Müller, T	1
Fuller, MA; Tolbert, SR	1
Cotman, CW; Ernesto, C; Growdon, J; Grundman, M; Klauber, MR; Pfeiffer, E; Sano, M; Schafer, K; Schneider, LS; Thal, LJ; Thomas, RG; Woodbury, P	1
Drachman, DA; Leber, P	1
Aisen, PS; Fine, E; Green, C; Lawlor, BA; Schmeïdler, J	1
Pincus, MM	1
Kilander, L; Ohrvall, M	1
Adelman, A	1
Oakley, F; Sunderland, T	1
Maloteaux, JM	1
Cohen, S; Freedman, M; Gordon, AS; Logan, AG; Rewilak, D; Shandling, M; Xerri, T	1
Cox, C; Frambes, N; Goldstein, B; Podgorski, CA; Tariot, PN	1
Cummings, JL; Tom, T	1
Schneider, LS	1
O'Toole, D	1
Sunderland, T; Tune, LE	1
Retz, W; Riederer, P; Rösler, M; Thome, J	1
Bhattacharjya, A; Brod, M; Brodaty, H; Dor, A; Feldman, H; Forette, F; Gauthier, S; Hay, J; Henke, C; Hill, S; Mastey, V; Neumann, P; O'Brien, B; Pugner, K; Sano, M; Sawada, T; Shostak, D; Stone, R; Whitehouse, PJ; Wimo, A; Winblad, B	1
Filip, V; Kolibás, E	1
Pryse-Phillips, W	1
Zarajczyk, M	1
Ballesteros, J; Jaúregui, JV; Meana, JJ; Ruiz, J; Soto, J; Ulibarri, I	1
Grundman, M	1
Cummings, J; Fillit, H	1
Delanty, N; Praticò, D	1
Klegeris, A; McGeer, PL	1
Gavrilova, SI; Zharikov, GA	1
Birks, J; Evans, SJ; Whitehead, A; Wilcock, GK	1
Lalonde, F; Lawlor, B; Martinez, R; Martinson, H; Mellow, A; Molchan, S; Putnam, K; Sunderland, T	1
Schneider, LS; Sobin, PB	1
Kovács, A	1
Hawkins, JW	1
Finali, G; Oliani, C; Piccinin, GL; Piccirilli, M	2
Agnoli, A; Fabbrini, G; Fioravanti, M; Martucci, N	1
Blandini, F; Bono, G; Martignoni, E; Merlo, P; Nappi, G; Sinforiani, E	1
Gillberg, PG; Gottfries, CG; Jossan, SS; Karlsson, I; Oreland, L	2
Lees, AJ	1
Bassi, S; Frattola, L; Grassi, MP; Mangoni, A; Marcone, A; Motta, A; Piolti, R; Smirne, S	1
Davis, CM; Fuselier, CC; Goad, DL; Liem, P; McCormack, JR; Olsen, KM	1
Finali, G; Piccinin, GL; Piccirilli, M	1
Cohen, RM; Mellow, AM; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN	1
Anttila, M; Heinonen, EH; Kotila, M; Lamintausta, R; Myllylä, V; Rinne, UK; Salonen, JS; Savijärvi, M; Sotaniemi, K	1
Eisenhofer, G; Goldstein, DS; Keiser, HR; Kopin, IJ; Murphy, DL; Stull, R; Sunderland, T	1
Cohen, RM; Mellow, AM; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN; Weingartner, H; Yount, D	1
Cohen, RM; Murphy, DL; Sunderland, T; Tariot, PN; Thompson, K; Weingartner, H; Welkowitz, JA	1
Martini, E; Pataky, I; Szilágyi, K; Venter, V	1
Cohen, RM; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN	1

Reviews

44 review(s) available for selegiline and Acute Confusional Senile Dementia

Article	Year
Multi-target-directed ligands to combat neurodegenerative diseases. Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid	2008
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Molecular psychiatry, 2016, Volume: 21, Issue:11 Topics: Aging; Alzheimer Disease; Animals; Brain; Catecholamines; Depressive Disorder, Major; Dopamine; History, 20th Century; Humans; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Rats; Selegiline	2016
Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:15 Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine; Selegiline; Severity of Illness Index; Vitamin E	2008
[The feasibility of synthetic enhancer substances for preventive nanotherapy]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:3 Topics: Alzheimer Disease; Animals; Brain Stem; Catecholamines; Depressive Disorder; Feasibility Studies; Humans; Liposomes; Nanomedicine; Neurons; Nootropic Agents; Parkinson Disease; Preventive Medicine; Selegiline; Serotonin; Ubiquitin-Protein Ligases	2010
[Monoamine oxidase inhibitors: prospects for the use in clinical practice]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:8 Topics: Alzheimer Disease; Animals; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Selegiline; Tourette Syndrome	2002
Selegiline for Alzheimer's disease. The Cochrane database of systematic reviews, 2003, Issue:1 Topics: Alzheimer Disease; Humans; Monoamine Oxidase Inhibitors; Randomized Controlled Trials as Topic; Selegiline; Treatment Failure	2003
[Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2003, Volume: 121, Issue:3 Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Parkinson Disease; Selegiline; Synaptic Transmission; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2003
Noncholinergic treatment options for Alzheimer's disease. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 9 Topics: Aged; Alzheimer Disease; Animals; Anticholesteremic Agents; Antioxidants; Behavioral Symptoms; Clinical Trials as Topic; Cognition Disorders; Estrogens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Patient Selection; Research Design; Selegiline; Vitamin E	2003
Pharmacologic treatment of Alzheimer's disease: an update. American family physician, 2003, Oct-01, Volume: 68, Issue:7 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Drug Monitoring; Estrogens; Ginkgo biloba; Humans; Neuroprotective Agents; Phytotherapy; Practice Guidelines as Topic; Selegiline; Vitamin E	2003
[Mild cognitive impairment]. Ryoikibetsu shokogun shirizu, 2003, Issue:40 Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Disease Progression; Humans; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index; Vitamin E	2003
[Prognosis in Alzheimer's disease]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Indans; Mental Processes; Piperidines; Prognosis; Risk; Selegiline; Survival Rate; Time Factors; Vitamin E	2004
Dementia. Clinical evidence, 2004, Issue:11 Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E	2004
Treatment possibilities of Alzheimer's disease. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2004, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Antiparkinson Agents; Benzofurans; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Genetic Predisposition to Disease; Humans; Mesencephalon; Neuroprotective Agents; Parkinson Disease; Reproducibility of Results; Research Design; Selegiline; United States	2004
[Alzheimer's disease therapy--theory and practice]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2005, Volume: 58, Issue:9-10 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Ginkgo biloba; Humans; Neuroprotective Agents; Nootropic Agents; Phytotherapy; Piracetam; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Selegiline	2005
Dementia. Clinical evidence, 2005, Issue:14 Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine	2005
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Transfer; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Selegiline; Severity of Illness Index; Treatment Outcome; Vitamin E	2006
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Current Alzheimer research, 2006, Volume: 3, Issue:5 Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Humans; Hydroxyquinolines; Indans; Models, Biological; Neuroprotective Agents; Parkinson Disease; Selegiline	2006
Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1995, Volume: 49, Issue:4 Topics: Aging; Alzheimer Disease; Animals; Antiparkinson Agents; Drug Administration Schedule; Humans; Parkinson Disease; Selegiline; Substantia Nigra	1995
Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Progress in neurobiology, 1994, Volume: 44, Issue:2 Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Depressive Disorder; Humans; Longevity; Mental Disorders; Monoamine Oxidase Inhibitors; Nervous System Diseases; Parkinson Disease; Schizophrenia; Selegiline	1994
Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Annals of the New York Academy of Sciences, 1994, Nov-17, Volume: 738 Topics: 1-Methyl-4-phenylpyridinium; Alzheimer Disease; Animals; Antioxidants; Corpus Striatum; Free Radicals; Humans; Hydroxyl Radical; Lipid Peroxidation; Monoamine Oxidase; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra	1994
Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: Alzheimer Disease; Depressive Disorder; Drug Synergism; Humans; Parkinson Disease; Selegiline; Substance-Related Disorders	1994
L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. Journal of the American Geriatrics Society, 1993, Volume: 41, Issue:11 Topics: Aged; Alzheimer Disease; Analysis of Variance; Behavior; Cognition; Double-Blind Method; Female; Humans; Interview, Psychological; Male; Neuropsychological Tests; Orientation; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index	1993
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. Journal of neural transmission. Supplementum, 1993, Volume: 40 Topics: Aging; Alzheimer Disease; Animals; Avoidance Learning; Catalase; Corpus Striatum; Drug Therapy, Combination; Learning; Levodopa; Male; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase	1993
Treatment of Parkinson's disease. Current opinion in neurology and neurosurgery, 1993, Volume: 6, Issue:3 Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline	1993
Lewy body diseases with dementia: pathophysiology and treatment. Brain and cognition, 1995, Volume: 28, Issue:3 Topics: Alzheimer Disease; Cerebral Cortex; Corpus Striatum; Humans; Lewy Bodies; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Substantia Nigra	1995
Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Progress in brain research, 1995, Volume: 106 Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Dementia; Disease Models, Animal; Dogs; Humans; Selegiline	1995
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Expression Regulation; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neurites; Neuroglia; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Protein Synthesis Inhibitors; Rats; Selegiline	1996
The clinical potential of Deprenyl in neurologic and psychiatric disorders. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome	1996
Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. The Annals of pharmacotherapy, 1996, Volume: 30, Issue:10 Topics: Alzheimer Disease; Behavior; Clinical Trials as Topic; Cognition; Humans; Monoamine Oxidase Inhibitors; Selegiline	1996
New cholinergic therapies: treatment tools for the psychiatrist. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 13 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinergic Agents; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens; Female; Humans; Indans; Male; Piperidines; Selective Serotonin Reuptake Inhibitors; Selegiline; Tacrine; Vitamin E	1998
Free radicals in Alzheimer's dementia: currently available therapeutic strategies. Journal of neural transmission. Supplementum, 1998, Volume: 54 Topics: Alzheimer Disease; Antioxidants; Drugs, Chinese Herbal; Free Radical Scavengers; Free Radicals; Humans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Piperazines; Psychotropic Drugs; Selegiline; Thiophenes; Vitamins	1998
Do we have drugs for dementia? No. Archives of neurology, 1999, Volume: 56, Issue:6 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phytotherapy; Piperidines; Plants, Medicinal; Selegiline; Tacrine; Vitamin E	1999
Vitamin E and Alzheimer disease: the basis for additional clinical trials. The American journal of clinical nutrition, 2000, Volume: 71, Issue:2 Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Clinical Trials as Topic; Cognition Disorders; Humans; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E	2000
Selegiline for Alzheimer's disease. The Cochrane database of systematic reviews, 2000, Issue:2 Topics: Alzheimer Disease; Humans; Monoamine Oxidase Inhibitors; Selegiline	2000
(-)Deprenyl (Selegiline): past, present and future. Neurobiology (Budapest, Hungary), 2000, Volume: 8, Issue:2 Topics: Aging; Alzheimer Disease; Animals; Brain Chemistry; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2000
Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. The American journal of medicine, 2000, Volume: 109, Issue:7 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Ascorbic Acid; Benzoquinones; Central Nervous System; Central Nervous System Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Free Radicals; Ginkgo biloba; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidation-Reduction; Phytotherapy; Plants, Medicinal; Selegiline; Ubiquinone; Vitamin E	2000
[Current strategies of pathogenetic therapy of Alzheimer's disease]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2001, Issue:7 Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors	2001
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS drug reviews, 2001,Fall, Volume: 7, Issue:3 Topics: Aging; Alzheimer Disease; Animals; Benzofurans; Brain; Catecholamines; Depression; Humans; Neuroprotective Agents; Parkinson Disease; Propylamines; Selegiline; Serotonin	2001
The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. International journal of geriatric psychiatry, 2002, Volume: 17, Issue:2 Topics: Aged; Alzheimer Disease; Double-Blind Method; Humans; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2002
Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacology bulletin, 1992, Volume: 28, Issue:1 Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Buspirone; Carbamazepine; Dementia; Humans; Lithium; Neurotransmitter Uptake Inhibitors; Selegiline; Serotonin; Trazodone	1992
["Widening horizons" in the clinical application of selegiline]. Acta pharmaceutica Hungarica, 1992, Volume: 62, Issue:5 Topics: Alzheimer Disease; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	1992
The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacology & toxicology, 1992, Volume: 70, Issue:5 Pt 1 Topics: Alzheimer Disease; Animals; Brain; Humans; Parkinson Disease; Selegiline	1992
(-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. Journal of the American Geriatrics Society, 1992, Volume: 40, Issue:8 Topics: Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Parkinson Disease; Rats; Receptors, Dopamine; Selegiline; Substantia Nigra	1992
Selegiline hydrochloride and cognition. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Aged; Alzheimer Disease; Attention; Dementia; Depressive Disorder; Humans; Mental Recall; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Reaction Time; Selegiline	1991

Trials

26 trial(s) available for selegiline and Acute Confusional Senile Dementia

Article	Year
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:5 Topics: Aged; Alzheimer Disease; Blood Platelets; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Female; Humans; Male; Malonates; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Selegiline	2009
Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease. Dementia and geriatric cognitive disorders, 2003, Volume: 16, Issue:1 Topics: Aged; Alzheimer Disease; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Neuroprotective Agents; Prospective Studies; Selegiline; Treatment Outcome	2003
L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. Journal of the American Geriatrics Society, 1993, Volume: 41, Issue:11 Topics: Aged; Alzheimer Disease; Analysis of Variance; Behavior; Cognition; Double-Blind Method; Female; Humans; Interview, Psychological; Male; Neuropsychological Tests; Orientation; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index	1993
Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 5, Issue:3 Topics: Aged; Alzheimer Disease; Biogenic Monoamines; Double-Blind Method; Female; Humans; Monoamine Oxidase Inhibitors; Norepinephrine; Pilot Projects; Psychiatric Status Rating Scales; Selegiline; Tryptophan	1993
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. The American journal of psychiatry, 1993, Volume: 150, Issue:2 Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Physostigmine; Pilot Projects; Psychiatric Status Rating Scales; Selegiline; Tacrine	1993
L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. Journal of the American Geriatrics Society, 1993, Volume: 41, Issue:4 Topics: Aged; Alzheimer Disease; Behavior; Cognition; Double-Blind Method; Educational Status; Female; Geriatric Assessment; Humans; Interview, Psychological; Male; Mental Status Schedule; Neuropsychological Tests; Selegiline; Severity of Illness Index	1993
L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry research, 1995, Oct-16, Volume: 58, Issue:3 Topics: Administration, Oral; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Mental Recall; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Physostigmine; Retention, Psychology; Selegiline; Treatment Outcome; Verbal Learning	1995
Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer disease and associated disorders, 1996,Fall, Volume: 10, Issue:3 Topics: Aged; Alzheimer Disease; Female; Humans; Male; Multicenter Studies as Topic; Neuropsychological Tests; Research Design; Selegiline; Vitamin E	1996
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England journal of medicine, 1997, Apr-24, Volume: 336, Issue:17 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Disease Progression; Double-Blind Method; Drug Combinations; Female; Humans; Institutionalization; Male; Mental Status Schedule; Monoamine Oxidase Inhibitors; Proportional Hazards Models; Selegiline; Treatment Outcome; Vitamin E	1997
Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. International journal of geriatric psychiatry, 1997, Volume: 12, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Geriatric Assessment; Humans; Male; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Psychiatric Status Rating Scales; Selegiline; Social Behavior Disorders	1997
Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study. International psychogeriatrics, 1997, Volume: 9, Issue:2 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Motor Skills; Neuropsychological Tests; Nootropic Agents; Physostigmine; Pilot Projects; Problem Solving; Psychometrics; Reproducibility of Results; Selegiline; Treatment Outcome	1997
L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology, 1998, Volume: 50, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Behavior; Cognition; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Psychiatric Status Rating Scales; Selegiline; Sensitivity and Specificity; Time Factors	1998
Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1998,Spring, Volume: 6, Issue:2 Topics: Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Monoamine Oxidase Inhibitors; Selegiline; Severity of Illness Index; Time Factors	1998
First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer disease and associated disorders, 1998, Volume: 12, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Humans; Indans; Middle Aged; Models, Economic; Neuroprotective Agents; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Selegiline	1998
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. Journal of psychiatry & neuroscience : JPN, 1999, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Memory Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neuropsychological Tests; Prospective Studies; Selegiline	1999
A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. International psychogeriatrics, 1992, Volume: 4 Suppl 2 Topics: Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Neuropsychological Tests; Physostigmine; Selegiline	1992
Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Italian journal of neurological sciences, 1992, Volume: 13, Issue:2 Topics: Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Selegiline; Verbal Learning	1992
CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1992, Volume: 2, Issue:1 Topics: Aged; Alzheimer Disease; Attention; Cerebrovascular Circulation; Cognition; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Memory; Monoamine Oxidase Inhibitors; Selegiline; Tomography, Emission-Computed, Single-Photon	1992
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:1 Topics: Aged; Alzheimer Disease; Biogenic Monoamines; Cognition; Dopamine; Double-Blind Method; Epinephrine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Neuropsychological Tests; Norepinephrine; Psychiatric Status Rating Scales; Psychological Tests; Selegiline	1991
L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clinical neuropharmacology, 1991, Volume: 14, Issue:6 Topics: Aged; Alzheimer Disease; Amnesia; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Selegiline; Verbal Learning	1991
Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. European neurology, 1991, Volume: 31, Issue:2 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Double-Blind Method; Humans; Male; Middle Aged; Neuropsychological Tests; Prognosis; Selegiline	1991
The use of selegiline in Alzheimer's patients with behavior problems. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cognition Disorders; Female; Home Nursing; Humans; Male; Mental Disorders; Middle Aged; Psychiatric Status Rating Scales; Selegiline; Single-Blind Method	1991
Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clinical neuropharmacology, 1990, Volume: 13, Issue:2 Topics: Aged; Alzheimer Disease; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Monoamine Oxidase; Neuropsychological Tests; Phenethylamines; Selegiline	1990
L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Archives of general psychiatry, 1987, Volume: 44, Issue:5 Topics: Adult; Aged; Alzheimer Disease; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Phenethylamines; Placebos; Psychiatric Status Rating Scales; Pulse; Selegiline	1987
Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology, 1987, Volume: 91, Issue:4 Topics: Adult; Aged; Alzheimer Disease; Attention; Cognition; Humans; Memory; Middle Aged; Phenethylamines; Psychomotor Performance; Selegiline	1987
Tranylcypromine compared with L-deprenyl in Alzheimer's disease. Journal of clinical psychopharmacology, 1988, Volume: 8, Issue:1 Topics: Aged; Alzheimer Disease; Female; Humans; Male; Middle Aged; Phenethylamines; Psychiatric Status Rating Scales; Selegiline; Tranylcypromine	1988

Other Studies

56 other study(ies) available for selegiline and Acute Confusional Senile Dementia

Article	Year
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Journal of medicinal chemistry, 2002, Nov-21, Volume: 45, Issue:24 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; Cattle; Cholinesterase Inhibitors; Humans; Indans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenethylamines; Propylamines; Structure-Activity Relationship	2002
Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. Journal of medicinal chemistry, 2012, Oct-11, Volume: 55, Issue:19 Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Antioxidants; Benzylidene Compounds; Cations, Divalent; Chelating Agents; Copper; Humans; Indans; Iron; Isoenzymes; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship; Zinc	2012
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. European journal of medicinal chemistry, 2014, Jun-10, Volume: 80 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Hep G2 Cells; Humans; Hydroxyquinolines; Indans; Male; Memory; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Piperidines; Propylamines; Rats	2014
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease. Bioorganic & medicinal chemistry, 2015, Jul-01, Volume: 23, Issue:13 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cations, Divalent; Cell Membrane Permeability; Chelating Agents; Copper; Humans; Iron; Membranes, Artificial; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Reactive Oxygen Species; Selegiline; Solutions; Zinc	2015
New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. European journal of medicinal chemistry, 2016, Oct-04, Volume: 121 Topics: Alzheimer Disease; Amines; Animals; Antioxidants; Cell Line, Tumor; Cholinesterases; Drug Design; Humans; Male; Mice; Molecular Targeted Therapy; Monoamine Oxidase; Neuroprotective Agents; Piperidines	2016
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzyl Compounds; Binding Sites; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Piperidines; Protein Aggregation, Pathological; Protein Binding; Structure-Activity Relationship	2017
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European journal of medicinal chemistry, 2018, Aug-05, Volume: 156 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; Enzyme Inhibitors; Flavonoids; Humans; Indans; Lipoxygenase Inhibitors; Male; Mice, Inbred BALB C; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurogenesis; Neuroprotective Agents; Piperidines; Receptors, sigma; Sigma-1 Receptor	2018
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors	2018
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 05-12, Volume: 94, Issue:19 Topics: Adult; Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Carbon Radioisotopes; Cerebral Cortex; Deuterium; Female; Heterozygote; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neuroimaging; Neuropsychological Tests; Positron-Emission Tomography; Presenilin-1; Prodromal Symptoms; Selegiline	2020
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:3(Special) Topics: Age Factors; Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Humans; Male; Monoamine Oxidase Inhibitors; Nootropic Agents; Pilot Projects; Random Allocation; Selegiline; Stroke; Time Factors; Treatment Outcome	2020
In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. Journal of Alzheimer's disease : JAD, 2021, Volume: 80, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Autopsy; Brain; Case-Control Studies; Female; Gliosis; Humans; Isoquinolines; Male; Middle Aged; Neuroglia; Plaque, Amyloid; Positron-Emission Tomography; Selegiline; Stilbenes	2021
Monoamine oxidase B inhibitor, selegiline, reduces Alzheimer's research & therapy, 2017, Mar-31, Volume: 9, Issue:1 Topics: Aged; Alzheimer Disease; Aminopyridines; Autoradiography; Binding, Competitive; Brain; Cognitive Dysfunction; Drug Interactions; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Selegiline; Supranuclear Palsy, Progressive; tau Proteins	2017
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nature communications, 2017, 04-03, Volume: 8 Topics: Alzheimer Disease; Animals; Apoptosis; Cell Death; Dendritic Spines; Dihydroxyphenylalanine; Disease Models, Animal; Dopaminergic Neurons; Food; Hippocampus; Inflammation; Memory; Mice, Transgenic; Nerve Degeneration; Neuronal Plasticity; Nucleus Accumbens; Plaque, Amyloid; Reward; Selegiline; Ventral Tegmental Area	2017
Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by Scientific reports, 2017, 04-04, Volume: 7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Autoradiography; Entorhinal Cortex; Female; Humans; Male; Microscopy, Fluorescence; Middle Aged; Parahippocampal Gyrus; Propanols; Quinolines; Selegiline; tau Proteins; Tritium	2017
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease. Science advances, 2019, Volume: 5, Issue:3 Topics: Alzheimer Disease; Animals; Astrocytes; Cognitive Dysfunction; D-Amino-Acid Oxidase; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline	2019
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. European journal of medicinal chemistry, 2013, Volume: 62 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Recombinant Proteins; Selegiline; Structure-Activity Relationship; Tacrine	2013
³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. Journal of neuroinflammation, 2013, Jul-23, Volume: 10 Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Astrocytes; Autoradiography; Benzothiazoles; Bungarotoxins; Cerebral Cortex; Female; Hippocampus; Humans; Immunohistochemistry; Isoquinolines; Isotope Labeling; Male; Nicotine; Parasympathetic Nervous System; Radionuclide Imaging; Receptors, Nicotinic; Selegiline; Synaptic Transmission; Thiazoles	2013
Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice. Neurochemical research, 2013, Volume: 38, Issue:11 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Selegiline	2013
Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:11 Topics: Alzheimer Disease; Carbon Radioisotopes; Female; Gliosis; Gray Matter; Hippocampus; Humans; Male; Middle Aged; Organ Size; Positron-Emission Tomography; Prodromal Symptoms; Selegiline	2014
Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:7 Topics: Aged; Alzheimer Disease; Aniline Compounds; Cerebellum; Cerebrovascular Circulation; Cognitive Dysfunction; Deuterium; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Gliosis; Gray Matter; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Perfusion; Pons; Positron-Emission Tomography; Radiopharmaceuticals; Selegiline; Thiazoles	2016
Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells. European journal of pharmacology, 2009, May-21, Volume: 610, Issue:1-3 Topics: ADAM Proteins; ADAM10 Protein; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Brefeldin A; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Neuroprotective Agents; PC12 Cells; Protein Kinase C-alpha; Protein Kinase C-epsilon; Protein Transport; Rats; Selegiline; Tetrazolium Salts; Thiazoles; Time Factors	2009
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochemistry international, 2011, Volume: 58, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Autoradiography; Brain; Disease Progression; Female; Gliosis; HLA Antigens; Humans; Immunohistochemistry; Isotope Labeling; Male; Microglia; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuritis; Radionuclide Imaging; Radiopharmaceuticals; Selegiline; Substrate Specificity; Up-Regulation	2011
Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization. International journal of pharmaceutics, 2011, Sep-20, Volume: 416, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Colloids; Cyanoacrylates; Drug Delivery Systems; Drug Design; Electrophoresis, Capillary; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Peptide Fragments; Polyethylene Glycols; Rhodamines; Selegiline	2011
In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study. European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Brain; Carbon Radioisotopes; Deuterium; Female; Gliosis; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Selegiline; Thiazoles; Tissue Distribution	2011
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:1 Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles; Brain; Case-Control Studies; Cognitive Dysfunction; Deuterium; Female; Fluorodeoxyglucose F18; Gliosis; Humans; Male; Middle Aged; Monoamine Oxidase; Neuropsychological Tests; Positron-Emission Tomography; Radioactive Tracers; Retrospective Studies; Selegiline; Thiazoles	2012
8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. ChemMedChem, 2012, Mar-05, Volume: 7, Issue:3 Topics: Alzheimer Disease; Coumarins; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Binding; Protein Isoforms; Selegiline; Solutions	2012
Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Medical hypotheses, 2004, Volume: 63, Issue:2 Topics: Acetylcarnitine; Alzheimer Disease; Brain; Cholinesterases; Cytidine Diphosphate Choline; Enzyme Activators; Humans; Meclofenoxate; Selegiline; Vitamin E	2004
Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:11 Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Alzheimer Disease; Caregivers; Conflict, Psychological; Cost of Illness; Decision Making; Family; Female; Humans; Male; Mental Status Schedule; Middle Aged; Professional-Family Relations; Selegiline; Spouses	2005
Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? International psychogeriatrics, 2007, Volume: 19, Issue:1 Topics: Aging; Alzheimer Disease; Antioxidants; Cognition Disorders; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E	2007
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Humans; Indans; Inhibition, Psychological; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase Inhibitors; Phenylcarbamates; Rivastigmine; Selegiline	2007
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs. Metabolic brain disease, 2009, Volume: 24, Issue:4 Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain Diseases; Cell Line, Tumor; Clorgyline; Endocytosis; Exocytosis; Hydrogen-Ion Concentration; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organelles; Pargyline; Parkinson Disease; Protons; Selegiline; Signal Transduction; Transport Vesicles	2009
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behavioural brain research, 2008, Jul-19, Volume: 190, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Association Learning; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indans; Male; Maze Learning; Mice; Mice, Inbred ICR; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Piperidines; Recognition, Psychology; Selegiline; Single-Blind Method; Statistics, Nonparametric	2008
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Aged; Aging; Alzheimer Disease; Brain; Central Nervous System; Female; Humans; Huntington Disease; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phenethylamines; Selegiline	1983
[Selegiline in the treatment of Alzheimer's disease]. Casopis lekaru ceskych, 1995, Jun-14, Volume: 134, Issue:12 Topics: Alzheimer Disease; Humans; Selegiline	1995
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less. The New England journal of medicine, 1997, Apr-24, Volume: 336, Issue:17 Topics: Alzheimer Disease; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Selegiline; Vitamin E	1997
Study suggests antioxidants slow decline in Alzheimer's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Jul-01, Volume: 54, Issue:13 Topics: Alzheimer Disease; Antioxidants; Disease Progression; Humans; Selegiline; Vitamin E	1997
Alpha-tocopherol and Alzheimer's disease. The New England journal of medicine, 1997, Aug-21, Volume: 337, Issue:8 Topics: Alzheimer Disease; Bias; Humans; Proportional Hazards Models; Selegiline; Survival Analysis; Vitamin E	1997
Alpha-tocopherol and Alzheimer's disease. The New England journal of medicine, 1997, Aug-21, Volume: 337, Issue:8 Topics: Aged; Alzheimer Disease; Cognition; Drug Therapy, Combination; Educational Status; Humans; Male; Selegiline; Vitamin E	1997
Selegiline and vitamin E in Alzheimer's disease. The Journal of family practice, 1997, Volume: 45, Issue:2 Topics: Aged; Alzheimer Disease; Disease Progression; Drug Combinations; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Reproducibility of Results; Selegiline; Treatment Outcome; Vitamin E	1997
[Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases]. Bulletin et memoires de l'Academie royale de medecine de Belgique, 1996, Volume: 151, Issue:10-11 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Parkinson Disease; Riluzole; Selegiline; Tacrine	1996
Drug treatment for Alzheimer's disease. The Western journal of medicine, 1998, Volume: 168, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Indans; Male; Neuroprotective Agents; Piperidines; Selegiline; Vitamin E	1998
Advances in the treatment of Alzheimer's disease. Aging (Milan, Italy), 1998, Volume: 10, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Controlled Clinical Trials as Topic; Humans; Neuroprotective Agents; Nootropic Agents; Selegiline; Tacrine; Vitamin E	1998
Debate regarding news story on cognitive dysfunction in dogs and cats. Journal of the American Veterinary Medical Association, 1998, Jul-15, Volume: 213, Issue:2 Topics: Alzheimer Disease; Animals; Cat Diseases; Cats; Cognition Disorders; Dog Diseases; Dogs; Humans; Neuroprotective Agents; Selegiline	1998
Alzheimer's disease management. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 13 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Middle Aged; Piperidines; Selegiline; Tacrine; Vitamin E	1998
[Jumex in the treatment of Alzheimer's disease]. Neurologia i neurochirurgia polska, 1999, Volume: 33 Suppl 1 Topics: Aged; Alzheimer Disease; Humans; Monoamine Oxidase Inhibitors; Selegiline	1999
I2-imidazoline receptors in platelets of patients with Parkinson's disease and Alzheimer's type dementia. Annals of the New York Academy of Sciences, 1999, Jun-21, Volume: 881 Topics: Alzheimer Disease; Antiparkinson Agents; Blood Platelets; Cell Membrane; Humans; Idazoxan; Imidazoles; Imidazoline Receptors; Kinetics; Parkinson Disease; Receptors, Drug; Reference Values; Selegiline	1999
Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Managed care interface, 2000, Volume: 13, Issue:1 Topics: Algorithms; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Caregivers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Donepezil; Drug Interactions; Estrogens; Female; Ginkgo biloba; Humans; Indans; Male; Managed Care Programs; Nootropic Agents; Patient Selection; Phytotherapy; Piperidines; Plants, Medicinal; Psychotropic Drugs; Quality of Health Care; Selegiline; Tacrine; Time Factors; Vitamin E	2000
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Experimental neurology, 2000, Volume: 166, Issue:2 Topics: Alzheimer Disease; DNA Primers; Gene Expression Regulation, Enzymologic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Monocytes; Nerve Degeneration; Neuroblastoma; Neurons; Neurotoxins; Parkinson Disease; RNA, Messenger; Selegiline; Tumor Cells, Cultured	2000
Nonsedating treatments for Alzheimer's patients with behavioral problems. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:3 Topics: Alzheimer Disease; Buspirone; Fluoxetine; Humans; Selegiline; Sleep; Trazodone	1992
Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience, 1991, Volume: 45, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Brain; Humans; Male; Middle Aged; Monoamine Oxidase; Selegiline	1991
Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study. Journal of neural transmission. Supplementum, 1990, Volume: 32 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Brain; Brain Mapping; Humans; Male; Microtomy; Monoamine Oxidase; Selegiline	1990
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology, 1987, Volume: 91, Issue:3 Topics: Aging; Alzheimer Disease; Biogenic Amines; Dose-Response Relationship, Drug; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylglycol; Middle Aged; Phenethylamines; Selegiline	1987
Pharmacokinetics and metabolism of selegiline. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Aged; Alzheimer Disease; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline	1989
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clinical chemistry, 1986, Volume: 32, Issue:11 Topics: Alzheimer Disease; Animals; Catecholamines; Chromatography, Liquid; Depression; Dihydroxyphenylalanine; Dogs; Glycols; Humans; Methoxyhydroxyphenylglycol; Monoamine Oxidase Inhibitors; Posture; Quality Control; Selegiline; Tranylcypromine	1986
Brief information on an early phase-II study with deprenyl in demented patients. Pharmacopsychiatry, 1987, Volume: 20, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Drug Evaluation; Female; Humans; Phenethylamines; Selegiline	1987